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The SPf66 synthetic vaccine is safe and partly efficaciousagainst Plasmodium falciparum malaria
among children 1-5 years old. The estimated vaccine efficacy [VE] for all clinical episodes over a
period of 18 months after the third dose is 25% (95% confidence interval [CI], 1%-44%; P = .044).
The observed temporal variations in efficacy could have been due to chance (likelihood ratio r =
13.8,8 df; P = .086). Efficacy against clinical malaria did not vary significantly with age cr = 1.07,
4 df; P = .90). Overall parasite density was 21% lower in vaccine recipients than in the placebo
group (95% CI, 0%-38%; P = .044). Further development of SPf66 may require trials to evaluate
safety, immunogenicity, and efficacy when administered in the first year of life, together with other
vaccines contained in the Expanded Programme of Tmmunization schedule.
Malaria, especially that caused by Plasmodium falciparum,
is the most important parasitic disease of humans. Estimates
of the burden of disease and death are imprecise but include
> 300 million clinical episodes and 1-3 million deaths per
year. Even though malaria has a wide geographic distribution
and is endemic in> 100 countries, >90% of the world's burden
of disease and death concentrates among young children and
primigravid pregnant women living in sub-Saharan Africa.
Development of vaccines against P. falciparum offers multi-
ple potential targets in all stages of the parasite's life cycle,
and technological developments allow for the possibility of
combining antigens from either one or several stages. Each
target or combination of targets may possibly imply different
outcomes. In the absence of a pre - erythrocytic stage vaccine
that induces sterilizing lifelong immunity (clearly the most
desirable option), vaccines derived from asexual-blood stage
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antigens may be of particular interest in Africa, because they
may mimic the development of natural anti-parasite and clinical
immunity in children living in endemic areas [1].
SPf66 is a synthetic hybrid polymer, solubilized in saline
solution and adsorbed onto aluminium hydroxide. The mono-
mer unit is a chemically synthesized peptide of 45 amino acids
that contains sequences derived from three asexual-blood stage
proteins (83, 55, and 35 kDa) linked by repeat sequences from
the circumsporozoite protein of the P. falciparum parasite [2].
SPf66 has been shown to be safe and partially protective against
P. falciparum malaria in populations> I year of age living in
low-endemicity areas of South America [3, 4, 5]. In the La
Tola trial in Colombia [3], SPf66 was efficacious for at least
1 year after the third dose, and there was a suggestion that
efficacy was higher among young children and older adults.
However, all of the effects of SPf66, including safety, immuno-
genicity, and short- and long-term efficacy, could vary with
different transmission levels.
The first safety, immunogenicity, and efficacy results of
SPf66 from Africa came from a trial in the Kilombero Valley,
an area of intense perennial transmission of P. falciparum in
southern Tanzania [6, 7]. In the study, the efficacy analysis of
the SPf66 vaccine in 1- to 5-year-old children indicated that
three doses reduced the risk of first or only episodes of clinical
malaria by 31% (95% confidence interval [CI], 0%-52%; P
= .045) [7]. Clinical malaria was defined as fever (axillary
temperature ;::::37.5°C) with parasite density >20,OOOlflL. The
efficacy against all episodes of fever and parasitemia (a less
specific case definition of clinical malaria), though lower than
that against hyperparasitemic episodes, was 25% (95% CI, 2%-
43%; P = .03). Thus, the vaccine had partial efficacy against
clinical malaria during 1 year following administration of the
third dose. Longer-term protection remained to be established,
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including a theoretically possible rebound in morbidity among
vaccine recipients if immunity induced by the vaccine de-
creased over time. More recently, a trial among nonimmune
Gambian infants, who were 6- to l l-rnonths old at the time of
the tirst dose, has failed to document significant levels
of protection (vaccine efficacy [VEl = 8%; 95% CI, -18%-
29%) [8].
Here we report further analyses of the data from the Kilom-
bero SPf66 trial. We examine whether vaccine efficacy extends
beyond the tirst year of follow-up, whether there is evidence
to suggest that efficacy varies with age, and the effect of the
vaccine on parasite density in more detail.
Methods
Study area and period. The study was done in the village of
Idete in the Kilombero river plain in southern Tanzania. Details
of the study area and study design have been presented elsewhere
[9, 10]. In brief, the Kilombero Valley is an area of intense and
perennial malaria transmission. Most inhabitants are subsistence
farmers growing maize and natural irrigation rice. The Kilombero
SPf66 vaccine trial was a randomized double-blind, placebo-con-
trolled, community-based efficacy trial. After screening procedures
were completed, 586 children aged 1-5 years received three doses
of either SPf66 or placebo.
The main analyses presented here are based on the period start-
ing 4 weeks after the administration of the third dose of vaccine
(September 1993). The previously reported analyses [7] considered
follow-up for 48 weeks, until the end of July 1994. We now
describe results including an extended follow-up for a further 26
weeks, terminating on 31 January 1995. Although the randomiza-
tion code was broken in early August 1994 for the analysis, the
study population and field team remained blind for the extra period
of follow-up, while further supplies of SPf66 were prepared and
transported to Tanzania. In the first week of February 1995, SPf66
was offered to children who had previously received placebo, as
agreed between the village and the investigators at the beginning
of the trial.
Parasitologic and clinical surveillance. Cross-sectional sur-
veys, at which blood films for parasitologic examination were
taken, were done on a group of 219 children during weeks 30, 32,
34, 38, 50, 73, and 99 of the follow-up (4, 6, 8, 12, 24, 47, and
73 weeks, respectively, after the third dose). Similar surveys were
also done between the second and third doses on a different sub-
group of 176 children at weeks 8, 10, 12, 16, and 24. All 586
children making up the complete study cohorts were seen at a
baseline survey 2 weeks before receiving the first dose [10]. Before
each dose of either vaccine or placebo, all study children received
one dose of sulfadoxine-pyrimethamine (25 mg of sulfadoxine and
0.75 mg of pyrimethamine/kg of body weight).
Passive case detection of clinical episodes was done at the only
village dispensary as described [7, 10]. In brief, each patient at-
tending the dispensary for a perceived illness was screened by
project medical personnel, who provided 24-h coverage. Children
were identified using the census and individual identification cards,
and axillary temperatures were checked with an electronic ther-
mometer (MBO, Munich). If the temperature was ~37.5°C, a fin-
gerprick blood sample was collected and thick and thin blood films
prepared. Children were then cared for by the routine medical
services at the dispensary. Clinically suspected malaria episodes
were treated, following national standard guidelines, with 25 mg/
kg chloroquine.
Statistical methods. Analysis of risk of clinical malaria consid-
ered all episodes satisfying the primary case definition (>20,000
parasites/ul. and an axillary temperature ~37.5°C). Note that this
differs from previous analysis [7], which were restricted to first
or only episodes. For the present analyses, time at risk was com-
puted in weeks. Any week that included days at risk was included.
To avoid the inclusion of treatment failures and recrudescence as
repeated events, second events <28 days after an episode were
excluded. Children were not considered at risk for those 28 days.
The proportion of the weeks at risk in which an episode occurred
was analyzed by logistic regression using the EGRET software
package [11]. Because there were small imbalances between vac-
cine and placebo groups with respect to age and distance from the
dispensary [7], all analyses allowed for these factors as defined in
the analytical plan [7]. Analysis also considered effects of vaccina-
tion status and of time periods of ~8 weeks. The age-dependence
of the effect of vaccination was tested by including a term repre-
senting age for vaccine recipients and °for placebo recipients.
Changes in vaccine efficacy over time were tested similarly.
The above analyses assume that multiple episodes in the same
child occur independently of each other. To test whether this as-
sumption affected the conclusions, a logistic-normal regression
model [12] was fitted, which allowed for variation in susceptibility
between children. Adjusting for this potential source of variation
did not improve the fit of the model, and we therefore report tests
and CIs derived from the original analysis.
Parasite positivity was analyzed by logistic regression in relation
to age group, vaccination status, and time period of the survey.
Allowance for variation between children in susceptibility again
did not improve the fit of the model.
Analyses of parasite densities were related to vaccination status,
survey, and age using least squares regression models. Aging of
the cohort meant that the age distribution was different at each
survey. Age-specific average parasite densities allowing for survey
variation were computed by the method of least squares means
[13]. The same method was used to calculate survey-specific aver-
age adjusted for age.
Parasite densities on successive slides from the same child are
correlated. Models that allowed for this were fitted by residual
maximum likelihood [14] using the SAS MIXED procedure [15].
Statistical significance test was determined by likelihood ratio (LR)
tests.
Results
Clinical episodes. During the additional 6 months of fol-
low-up from 1 August 1994 to 31 January 1995, there were
no deaths among cohort children. Twenty-nine episodes of
clinical malaria satisfying the primary case definition ( 10 vac-
cine and 19 placebo) were detected through passive case detec-
tion. Between 4 weeks after the third dose and the end of
follow-up 18 months later, a total of 121 clinical episodes were
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Figure 1. Incidence of clinical episodes among SPf66 vaccine and
placebo cohorts after third dose by 8-week time period.
recorded in placebo recipients (0.30 episodes/child-year) and
83 in SPf66 recipients (0.23 episodes/child-year). The age- and
distance-adjusted estimate of vaccine efficacy was 25% (95%
CI, 1%--44%; LR X2 = 4.04, I df; P = .044). The incidence of
clinical episodes, among both vaccine and placebo recipients,
showed a decline with time (figure I). Age-standardized inci-
dence estimates indicated that the decline in incidence over the
period of follow-up could not be entirely accounted for by the
aging of the cohort (age- and distance-adjusted tests of the
difference in risk between 2-month time periods, LR X2 =
43.4, 8 df; P < .001). Although vaccine efficacy appeared to
vary over time and to be restricted to several periods (figure
1), there was no clear trend, and these variations could have
been due to chance (test of heterogeneity in efficacy between
time periods, LR X2 = 13.8, 8 df; P = .086).
Risk of clinical malaria decreased steeply with age (table 1
and figure 2). Incidence of clinical malaria was lower among
vaccine recipients than among placebo recipients in all age
groups. The corresponding vaccine efficacy estimates by age
are also presented in table 1. There was no evidence of vaccine
efficacy changing with age (LR test for heterogeneity, X2 =
1.07, 4 df; P = .90; LR test for trend, X2 = 0.26, 1 df; P =
.69). In children <2.5 years of age, the vaccine efficacy of
29% corresponds to a time period- standardized reduction in
risk from 0.92 to 0.65 episodes per child-year (i.e., a substantial
reduction in risk of 0.27 prevented episodes per child-year).
The corresponding reduction in children > 5 years old, for
whom the estimated VE was 43%, was from 0.12 to 0.07
episodes per child-year (0.05 prevented episodes).
Parasite positivity. Treatment with sulfadoxine-pyrimeth-
amine before each dose of vaccine aimed to optimize the re-
Eighteen months after the third dose of SPf66 was given in
the Kilombero trial, there is evidence to suggest that vaccine
efficacy against clinical malaria was sustained. Previous analy-
ses of this trial indicated that the vaccine is safe and immuno-
genic and reduced the risk of first or only episodes of clinical
malaria by a best estimate of 31% during a I-year period of
follow-up after the third dose. By including a further 6 months
of follow-up, as well as all malaria episodes and not just first
or only episodes, we estimate vaccine efficacy to be 25% (95%
CI, 1%-44%). This figure therefore represents the reduction
in the burden ofmalaria attributable to vaccination in this group
of children over a period of 18 months after the third dose.
None of the published trials were designed to look at varia-
tions in efficacy over time, and observed data must be interpre-
ted with caution. The La Tola trial [3] suggested some degree
of variation in vaccine efficacy over time. However, there was
evidence of efficacy in all time periods and a suggestion that
efficacy was highest in the first and last 3-month period. The
apparent temporal variations in the trial of Las Majadas in
Venezuela [4] are very difficult to interpret given the nonran-
domized nature of the trial.
In the Tanzania trial (figure 1), there is a suggestion that
vaccine efficacy has been limited to certain time periods (Janu-
ary and September 1994 and January 1995). Although a number
of hypotheses related to transmission intensity or seasonal cir-
Discussion
sponse to the vaccine. It consequently also ensured that follow-
up began with a low prevalence of parasitemia in both vaccine
and placebo groups (figure 3). Prevalence increased rapidly
with time, gradually tending toward levels similar to that at
screening (92%). The difference between overall parasite posi-
tivity in vaccine and placebo groups was small and not statisti-
cally significant (LR X 2 = 2.25, 1 df, P = .13). The prevalence
of patent parasitemia averaged over all surveys declined with
age (LR X2 = 16.74,4 df, P = .002), but this decline was not
very steep. There was no evidence that the effect of vaccination
varied with age (LR X 2 = 0.26, 1 df, P = .6).
Parasite densities. Overall, parasite density after the third
dose was 21% lower in vaccine recipients than in the placebo
group (95% CI: 0%-38%; F statistic = 4.06, 1740 df, P =
.044). Parasite densities decreased with age, both after the third
dose (figure 4A, table 2) and between the second and third
doses (figure 4B). Allowance for differences between surveys
did not account for the age trends (LR test for effect of age
adjusted for survey, X2 = 28.16,4 df; P < .001). After the third
dose, parasite density was much more strongly age-dependent
among vaccine recipients than among placebo recipients. In
the youngest age group, the densities in children receiving three
doses of vaccine were higher than in placebo recipients, but
the reverse was true for older children. The interaction between
a linear effect of age and vaccination status was statistically
highly significant (LR X2 = 12.6, 1 d,f; P < .001).
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Table 1. Annual incidence of clinical episodes by age group among SPf6() vaccine and placebo recipients and corresponding vaccine efficacy
estimates.
Vaccine Placebo
Adjustd Adjusted
Age, No. of Weeks incidence No. of Weeks incidence Vaccine efficacy. 'Y.,
months episodes at risk rate* episodes at risk rate* (95'% confidence interval)
<30 24 1508 0.65 27 1220 0.92 29 (-24,59)
30-35 20 1900 0.56 24 1793 0.62 9 (~66, 50)
3647 19 3843 0.30 29 4653 0.31 5 (~70, 47)
48~59 II 3557 0.17 20 4021 0.25 32 (~42, 68)
~60 9 7765 0.07 21 9145 0.12 43 (-25, 74)
* Estimated incidence for fifth 8-week period of follow-up, adjusted for distance from dispensary.
culation of certain parasite strains could be postulated, the
apparent variations in vaccine efficacy over time may have
been simply due to chance. Nonetheless, one of those periods
when differences between vaccine and placebo recipients ap-
pear to be more noticeable is precisely at the end of the follow-
up. This would support the suggestion that the vaccine remains
efficacious for at least 18 months after the third dose. It would
also argue against decreasing vaccine efficacy or rebound in
morbidity among vaccine recipients.
The data also highlight the difficulty of establishing long-
term protection afforded by an asexual-stage vaccine in an area
ofhigh transmission where the age pattern of disease is strongly
shifted toward the younger age groups. Indeed, while children
< 30 months old had nearly I clinical episode detected through
passive case detection every year, children >60 months old
had just over 0.1 episodes per year. Other authors have argued
that even in areas of very high transmission, there are relatively
small differences in the incidence of malaria among children
aged 0-6 years and subject to a very intense and active follow-
up [16]. These children have, on average, 4 episodes per year.
While this may be true, our data clearly show that the risk of
clinical malaria cases that attend the dispensary and fulfill a
definition of clinical malaria with a high specificity decreases
steeply with age in this area of high and perennial transmission.
As previously argued [17], it may be that the cases seen at
the dispensary and therefore ascertained through passive case
detection represent the more severe episodes in the clinical
spectrum of malaria, while many other mild, self-limited, non-
severe cases go unreported.
The trial was not designed, and therefore had little power,
to demonstrate differences in vaccine efficacy between age
groups. In any case, the data suggest that clinical efficacy is
not restricted to children of any specific age group or that the
efficacy depends on age. Younger children seem to be protected
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Figure 2. Incidence of clinical episodes among SPf66 vaccine and
placebo recipients after third dose by age at time of episode.
Figure 3. Prevalence of parasitemia by time period among SPf66
vaccine and placebo recipients.
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Figure 4, Geometric mean parasite densities by age at time of epi-
sode after third dose of SPf66 vaccine (A) and between second and
third dose (B).
to a similar degree as older ones. The impact of even a modest
efficacy of 30% in the younger age groups is large, given the
high incidence of malaria in this age group, and corresponds
to 0.27 prevented episodes per child-year.
A primary effect of SPf66 on asexual-stage parasites was
anticipated because the vaccine includes amino acid sequences
derived from merozoite membrane proteins. In the original
artificial challenge experiments in Colombia in both monkeys
and humans [18, 19], self-limiting symptomatic infections were
observed in some immunized individuals, implying that a pri-
mary effect of SPf66 may be to reduce densities of blood-stage
parasites. In our trial, there is evidence of the vaccine reducing
parasite densities after the third dose by ~20%.
When comparing parasite densities between SPf66 and pla-
cebo recipients in different age groups, it appears that three
doses of vaccine were associated with a reduction in parasite
densities in the older children and with an apparent negative
effect in the youngest children. However, the comparison of
the age-dependence of densities after the third dose with those
in the baseline survey (figure 4A) and between the second and
third dose suggests that rather than the vaccine group showing
an unusually strong relationship between age and density, the
placebo group shows an unexpectedly weak age-dependence
of densities. The reason for this temporary decrease in age-
dependence is unclear. It may be a consequence of repeated
sulfadoxine-pyrimethamine treatment. This resulted in an ex-
tended period of reduced antigenic stimulation in the placebo
group at the same time as the vaccine group was being immu-
nized with SPf66. However, this may help explain the lower
parasite densities seen in the young children receiving placebo
but can hardly explain the higher parasite densities in older
children in the placebo group compared to baseline data.
Recently reported results from a trial of SPf66 among nonim-
mune Gambian infants 6- to l I-months old at the time of first
dose have not documented significant levels of protection [8].
The results raise further questions on the potential public health
relevance of the vaccine. Efficacy estimates were based on a
subgroup analysis of the study children and a short 3.5-month
period of follow-up. The authors suggest that the lack of a
significant level of protection documented in the SPf66 trial in
Gambia may have been due to the short follow-up and that it
may take the vaccine this long to show any apparent effect.
While this may be true, data on this point are lacking.
Some of the differences in the estimated efficacies between
the trial in Gambia and all other trials may include the design
and its emphasis on active case detection, the ages and level
of preimmunity of the study children, and the specificity of the
case definitions of the primary end point. It is also possible
that the apparently contradictory results between Gambia and
all other sites may have been due to chance, as the upper
95% confidence bound overlaps with the lower bound from
the Tanzanian trial. These results also highlight the need for
adequate coordination of trials that ensure complementarity
and comparability.
The benefit of any malaria vaccine in sub-Saharan Africa
will depend mainly on its effectiveness in preventing severe
disease and death. Its applicability is likely to depend on the
feasibility of delivering it through the Expanded Programme
of Immunization. Recent estimates suggest that a vaccine with
a 30% efficacy against death may be a highly cost-effective
public health intervention in countries of sub-Saharan Africa
in which malaria is endemic if it can be delivered through
the existing Expanded Programme of Immunization (Evans
D, personal communication). A further large-scale study to
investigate these questions and complete the process of vaccine
development for SPf66 is required [20]. Also, further work to
understand the reason for the different estimates of efficacy
between different trial sites is needed. The comprehensive ap-
proach to all these questions as well as a systematic review of
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Table 2. Geometric mean parasite densities by age group and treatment group between second and third dose and after third dose of either
vaccine or placebo.
Vaccine Placebo
Time point, Parasite Parasite Lower 95% Ratio of Upper 95'%
age (years) n density n density confidence limit* densities* confidence limit*
Between second and third dose
~2 80 3708 112 3817 0.56 0.97 1.69
3 42 2334 62 3449 0.34 0.6g 1.36
4 55 2315 62 2608 0.49 0.91 1.68
5 40 1441 52 1725 0.42 0.82 1.62
~6 14 1666 19 1689 0.34 1.00 2.90
After third dose
~2 100 3699 74 2288 0.98 1.67 2.84
3 77 2174 92 2284 0.50 0.82 1.32
4 72 1443 83 2046 0.41 0.69 1.14
5 52 1146 54 1910 0.29 0.54 1.00
~6 61 904 88 1930 0.28 0.45 0.73
* Allowing for differences between surveys in average densities.
all published and ongoing work on this vaccine will clarify the
potential of SPf66 as a potential public health tool and help in
the process of development of new vaccines with increased
efficacy.
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